The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
ACR/ARHP 2018 Annual Meeting
Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
ACR/ARHP 2017 Annual Meeting
Sarilumab administered every 2 weeks is associated with similar improvements in physical function in adult patients with rheumatoid arthritis, compared with adalimumab.
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.